Seven Eight Capital, LP Mirati Therapeutics, Inc. Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$36.54 - $54.26 $968,821 - $1.44 Million	-26,514 Reduced 61.28%	16,750 $622,000
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $1.79 Million - $4.27 Million	43,264 New	43,264 $1.96 Million
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $242,784 - $303,024	-1,686 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$162.05 - $240.27 $64,820 - $96,108	400 Added 31.1%	1,686 $370,000
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $145,652 - $215,109	1,286 New	1,286 $214,000
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $2.28 Million - $3.21 Million	-29,291 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$59.49 - $104.71 $1.74 Million - $3.07 Million	29,291 New	29,291 $3.02 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.